dbSNP Short Genetic Variations
Welcome to the Reference SNP (rs) Report
All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.
Reference SNP (rs) Report
This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.
rs1799853
Current Build 157
Released September 3, 2024
- Organism
- Homo sapiens
- Position
-
chr10:94942290 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
- Alleles
- C>A / C>T
- Variation Type
- SNV Single Nucleotide Variation
- Frequency
-
T=0.1180731 (165449/1401242, GnomAD_exomes)T=0.085923 (22743/264690, TOPMED)T=0.087353 (13028/149142, GnomAD_genomes) (+ 23 more)
- Clinical Significance
- Reported in ClinVar
- Gene : Consequence
- CYP2C9 : Missense Variant
- Publications
- 274 citations
- Genomic View
- See rs on genome
ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.
Release Version: 20231103111315
| Population | Group | Sample Size | Ref Allele | Alt Allele | Ref HMOZ | Alt HMOZ | HTRZ | HWEP |
|---|---|---|---|---|---|---|---|---|
| Total | Global | 140136 | C=0.891976 | T=0.108024 | 0.791074 | 0.007122 | 0.201804 | 32 |
| European | Sub | 107616 | C=0.878745 | T=0.121255 | 0.764979 | 0.00749 | 0.227531 | 32 |
| African | Sub | 8946 | C=0.9723 | T=0.0277 | 0.945898 | 0.001341 | 0.052761 | 1 |
| African Others | Sub | 330 | C=0.997 | T=0.003 | 0.993939 | 0.0 | 0.006061 | 0 |
| African American | Sub | 8616 | C=0.9713 | T=0.0287 | 0.944058 | 0.001393 | 0.05455 | 1 |
| Asian | Sub | 3216 | C=0.9988 | T=0.0012 | 0.997512 | 0.0 | 0.002488 | 0 |
| East Asian | Sub | 1958 | C=0.9995 | T=0.0005 | 0.998979 | 0.0 | 0.001021 | 0 |
| Other Asian | Sub | 1258 | C=0.9976 | T=0.0024 | 0.995231 | 0.0 | 0.004769 | 0 |
| Latin American 1 | Sub | 588 | C=0.871 | T=0.129 | 0.755102 | 0.013605 | 0.231293 | 0 |
| Latin American 2 | Sub | 1218 | C=0.9179 | T=0.0821 | 0.837438 | 0.001642 | 0.16092 | 2 |
| South Asian | Sub | 4930 | C=0.9538 | T=0.0462 | 0.907911 | 0.000406 | 0.091684 | 2 |
| Other | Sub | 13622 | C=0.89480 | T=0.10520 | 0.801938 | 0.012333 | 0.185729 | 1 |
Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").
Download| Study | Population | Group | Sample Size | Ref Allele | Alt Allele |
|---|---|---|---|---|---|
| gnomAD v4 - Exomes | Global | Study-wide | 1401242 | C=0.8819269 | T=0.1180731 |
| gnomAD v4 - Exomes | European | Sub | 1165256 | C=0.8686649 | T=0.1313351 |
| gnomAD v4 - Exomes | South Asian | Sub | 86254 | C=0.95096 | T=0.04904 |
| gnomAD v4 - Exomes | American | Sub | 44696 | C=0.92780 | T=0.07220 |
| gnomAD v4 - Exomes | East Asian | Sub | 39688 | C=0.99977 | T=0.00023 |
| gnomAD v4 - Exomes | African | Sub | 33460 | C=0.98051 | T=0.01949 |
| gnomAD v4 - Exomes | Ashkenazi Jewish | Sub | 26124 | C=0.86223 | T=0.13777 |
| gnomAD v4 - Exomes | Middle Eastern | sub | 5764 | C=0.8798 | T=0.1202 |
| TopMed | Global | Study-wide | 264690 | C=0.914077 | T=0.085923 |
| gnomAD v4 - Genomes | Global | Study-wide | 149142 | C=0.912647 | T=0.087353 |
| gnomAD v4 - Genomes | European | Sub | 78584 | C=0.87455 | T=0.12545 |
| gnomAD v4 - Genomes | African | Sub | 41536 | C=0.97648 | T=0.02352 |
| gnomAD v4 - Genomes | American | Sub | 15266 | C=0.90220 | T=0.09780 |
| gnomAD v4 - Genomes | East Asian | Sub | 5170 | C=0.9996 | T=0.0004 |
| gnomAD v4 - Genomes | South Asian | Sub | 4820 | C=0.9612 | T=0.0388 |
| gnomAD v4 - Genomes | Ashkenazi Jewish | Sub | 3472 | C=0.8646 | T=0.1354 |
| gnomAD v4 - Genomes | Middle Eastern | sub | 294 | C=0.861 | T=0.139 |
| Allele Frequency Aggregator | Total | Global | 140136 | C=0.891976 | T=0.108024 |
| Allele Frequency Aggregator | European | Sub | 107616 | C=0.878745 | T=0.121255 |
| Allele Frequency Aggregator | Other | Sub | 13622 | C=0.89480 | T=0.10520 |
| Allele Frequency Aggregator | African | Sub | 8946 | C=0.9723 | T=0.0277 |
| Allele Frequency Aggregator | South Asian | Sub | 4930 | C=0.9538 | T=0.0462 |
| Allele Frequency Aggregator | Asian | Sub | 3216 | C=0.9988 | T=0.0012 |
| Allele Frequency Aggregator | Latin American 2 | Sub | 1218 | C=0.9179 | T=0.0821 |
| Allele Frequency Aggregator | Latin American 1 | Sub | 588 | C=0.871 | T=0.129 |
| ExAC | Global | Study-wide | 121310 | C=0.908565 | T=0.091435 |
| ExAC | Europe | Sub | 73344 | C=0.87405 | T=0.12595 |
| ExAC | Asian | Sub | 25136 | C=0.96965 | T=0.03035 |
| ExAC | American | Sub | 11516 | C=0.93400 | T=0.06600 |
| ExAC | African | Sub | 10406 | C=0.97646 | T=0.02354 |
| ExAC | Other | Sub | 908 | C=0.905 | T=0.095 |
| 38KJPN | JAPANESE | Study-wide | 77444 | C=0.99991 | T=0.00009 |
| Korean Genome Project 4K | KOREAN | Study-wide | 7234 | C=0.9997 | T=0.0003 |
| 1000Genomes_30X | Global | Study-wide | 6404 | C=0.9499 | T=0.0501 |
| 1000Genomes_30X | African | Sub | 1786 | C=0.9910 | T=0.0090 |
| 1000Genomes_30X | Europe | Sub | 1266 | C=0.8712 | T=0.1288 |
| 1000Genomes_30X | South Asian | Sub | 1202 | C=0.9617 | T=0.0383 |
| 1000Genomes_30X | East Asian | Sub | 1170 | C=0.9983 | T=0.0017 |
| 1000Genomes_30X | American | Sub | 980 | C=0.904 | T=0.096 |
| 1000Genomes | Global | Study-wide | 5008 | C=0.9521 | T=0.0479 |
| 1000Genomes | African | Sub | 1322 | C=0.9917 | T=0.0083 |
| 1000Genomes | East Asian | Sub | 1008 | C=0.9990 | T=0.0010 |
| 1000Genomes | Europe | Sub | 1006 | C=0.8757 | T=0.1243 |
| 1000Genomes | South Asian | Sub | 978 | C=0.965 | T=0.035 |
| 1000Genomes | American | Sub | 694 | C=0.901 | T=0.099 |
| Genetic variation in the Estonian population | Estonian | Study-wide | 4480 | C=0.9163 | T=0.0837 |
| The Avon Longitudinal Study of Parents and Children | PARENT AND CHILD COHORT | Study-wide | 3854 | C=0.8664 | T=0.1336 |
| UK 10K study - Twins | TWIN COHORT | Study-wide | 3708 | C=0.8643 | T=0.1357 |
| PharmGKB Aggregated | Global | Study-wide | 2924 | C=0.8895 | T=0.1105 |
| PharmGKB Aggregated | PA152210110 | Sub | 696 | C=0.885 | T=0.115 |
| PharmGKB Aggregated | PA154393580 | Sub | 584 | C=0.885 | T=0.115 |
| PharmGKB Aggregated | PA130477743 | Sub | 452 | C=0.883 | T=0.117 |
| PharmGKB Aggregated | PA154221784 | Sub | 410 | C=0.873 | T=0.127 |
| PharmGKB Aggregated | PA149569284 | Sub | 358 | C=0.947 | T=0.053 |
| PharmGKB Aggregated | PA152209014 | Sub | 184 | C=0.864 | T=0.136 |
| PharmGKB Aggregated | PA130443042 | Sub | 160 | C=0.894 | T=0.106 |
| PharmGKB Aggregated | PA130491052 | Sub | 58 | C=0.84 | T=0.16 |
| PharmGKB Aggregated | PA130491237 | Sub | 22 | C=0.95 | T=0.05 |
| KOREAN population from KRGDB | KOREAN | Study-wide | 2922 | C=0.9997 | T=0.0003 |
| Genome of the Netherlands Release 5 | Genome of the Netherlands | Study-wide | 998 | C=0.878 | T=0.122 |
| Northern Sweden | ACPOP | Study-wide | 600 | C=0.918 | T=0.082 |
| Medical Genome Project healthy controls from Spanish population | Spanish controls | Study-wide | 534 | C=0.869 | T=0.131 |
| HapMap | Global | Study-wide | 316 | C=0.965 | T=0.035 |
| HapMap | African | Sub | 120 | C=1.000 | T=0.000 |
| HapMap | American | Sub | 106 | C=0.896 | T=0.104 |
| HapMap | Asian | Sub | 90 | C=1.00 | T=0.00 |
| FINRISK | Finnish from FINRISK project | Study-wide | 304 | C=0.885 | T=0.115 |
| Qatari | Global | Study-wide | 216 | C=0.894 | T=0.106 |
| SGDP_PRJ | Global | Study-wide | 42 | C=0.50 | T=0.50 |
| The Danish reference pan genome | Danish | Study-wide | 40 | C=0.90 | T=0.10 |
| Siberian | Global | Study-wide | 8 | C=0.5 | T=0.5 |
| Ancient Sardinia genome-wide 1240k capture data generation and analysis | Global | Study-wide | 6 | C=1.0 | T=0.0 |
Help
Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.
Genomic Placements
| Sequence name | Change |
|---|---|
| GRCh38.p14 chr 10 | NC_000010.11:g.94942290C>A |
| GRCh38.p14 chr 10 | NC_000010.11:g.94942290C>T |
| GRCh37.p13 chr 10 | NC_000010.10:g.96702047C>A |
| GRCh37.p13 chr 10 | NC_000010.10:g.96702047C>T |
| CYP2C9 RefSeqGene (LRG_1195) | NG_008385.2:g.9133C>A |
| CYP2C9 RefSeqGene (LRG_1195) | NG_008385.2:g.9133C>T |
Gene: CYP2C9, cytochrome P450 family 2 subfamily C member 9
(plus strand)
| Molecule type | Change | Amino acid[Codon] | SO Term |
|---|---|---|---|
| CYP2C9 transcript | NM_000771.4:c.430C>A | R [CGT] > S [AGT] | Coding Sequence Variant |
| cytochrome P450 2C9 | NP_000762.2:p.Arg144Ser | R (Arg) > S (Ser) | Missense Variant |
| CYP2C9 transcript | NM_000771.4:c.430C>T | R [CGT] > C [TGT] | Coding Sequence Variant |
| cytochrome P450 2C9 | NP_000762.2:p.Arg144Cys | R (Arg) > C (Cys) | Missense Variant |
Help
Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.
Allele: C= (allele ID:
175331
)
| ClinVar Accession | Disease Names | Clinical Significance |
|---|---|---|
| RCV000150377.13 | Warfarin response | Drug-Response |
| RCV000150378.13 | Warfarin response | Drug-Response |
Allele: T (allele ID:
23448
)
| ClinVar Accession | Disease Names | Clinical Significance |
|---|---|---|
| RCV000008920.10 | Warfarin response | Drug-Response |
| RCV000154312.13 | Warfarin response | Drug-Response |
| RCV000309101.12 | not specified | Likely-Benign |
| RCV000723560.12 | not provided | Other |
| RCV000787929.10 | Flurbiprofen response | Drug-Response |
| RCV000788093.10 | Lesinurad response | Drug-Response |
| RCV000788099.10 | Piroxicam response | Drug-Response |
| RCV001263463.10 | Phenytoin response | Drug-Response |
Help
Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".
| Placement | C= | A | T |
|---|---|---|---|
| GRCh38.p14 chr 10 | NC_000010.11:g.94942290= | NC_000010.11:g.94942290C>A | NC_000010.11:g.94942290C>T |
| GRCh37.p13 chr 10 | NC_000010.10:g.96702047= | NC_000010.10:g.96702047C>A | NC_000010.10:g.96702047C>T |
| CYP2C9 RefSeqGene (LRG_1195) | NG_008385.2:g.9133= | NG_008385.2:g.9133C>A | NG_008385.2:g.9133C>T |
| CYP2C9 transcript | NM_000771.4:c.430= | NM_000771.4:c.430C>A | NM_000771.4:c.430C>T |
| CYP2C9 transcript | NM_000771.3:c.430= | NM_000771.3:c.430C>A | NM_000771.3:c.430C>T |
| cytochrome P450 2C9 | NP_000762.2:p.Arg144= | NP_000762.2:p.Arg144Ser | NP_000762.2:p.Arg144Cys |
Help
Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.
124 SubSNP,
24 Frequency,
10 ClinVar
submissions
| No | Submitter | Submission ID | Date (Build) |
|---|---|---|---|
| 1 | HGBASE | ss2419885 | Nov 14, 2000 (89) |
| 2 | TSC-CSHL | ss4049526 | Nov 05, 2001 (101) |
| 3 | TSC-CSHL | ss5288363 | Oct 08, 2002 (108) |
| 4 | SNP500CANCER | ss5586420 | Mar 31, 2003 (113) |
| 5 | EGP_SNPS | ss12588496 | Dec 05, 2003 (119) |
| 6 | BIOVENTURES | ss32475972 | May 24, 2005 (136) |
| 7 | ABI | ss38570128 | Mar 13, 2006 (126) |
| 8 | APPLERA_GI | ss48404892 | Mar 13, 2006 (126) |
| 9 | SI_EXO | ss52052050 | Oct 16, 2006 (127) |
| 10 | PHARMGKB_COBRA | ss69365623 | May 17, 2007 (136) |
| 11 | PHARMGKB_COBRA | ss69366431 | May 17, 2007 (136) |
| 12 | PHARMGKB_PAT | ss69367174 | May 18, 2007 (127) |
| 13 | PHARMGKB_COBRA | ss69367460 | May 17, 2007 (136) |
| 14 | PHARMGKB_AB_DME | ss84158178 | Dec 15, 2007 (130) |
| 15 | BCMHGSC_JDW | ss88317380 | Mar 23, 2008 (129) |
| 16 | PHARMGKB_PBAT | ss105107894 | Feb 06, 2009 (130) |
| 17 | PHARMGKB_PEAR | ss105108089 | Feb 06, 2009 (130) |
| 18 | PHARMGKB_PEAR | ss105109746 | Feb 06, 2009 (130) |
| 19 | PHARMGKB_PBAT | ss105109762 | Feb 06, 2009 (130) |
| 20 | ILLUMINA | ss153736100 | Dec 01, 2009 (136) |
| 21 | ILLUMINA | ss159329689 | Dec 01, 2009 (136) |
| 22 | SEATTLESEQ | ss159721125 | Dec 01, 2009 (136) |
| 23 | ILLUMINA | ss160462691 | Dec 01, 2009 (136) |
| 24 | ILLUMINA | ss172924182 | Jul 04, 2010 (136) |
| 25 | COMPLETE_GENOMICS | ss174703200 | Jul 04, 2010 (132) |
| 26 | BCM-HGSC-SUB | ss207463445 | Jul 04, 2010 (132) |
| 27 | OMICIA | ss244238828 | May 27, 2010 (132) |
| 28 | BL | ss254535320 | May 09, 2011 (134) |
| 29 | OMIM-CURATED-RECORDS | ss256302166 | Aug 26, 2010 (132) |
| 30 | 1000GENOMES | ss336318562 | May 09, 2011 (134) |
| 31 | NHLBI-ESP | ss342304157 | May 09, 2011 (134) |
| 32 | ILLUMINA | ss410916035 | Sep 17, 2011 (135) |
| 33 | ILLUMINA | ss481066559 | Sep 08, 2015 (146) |
| 34 | 1000GENOMES | ss491001666 | May 04, 2012 (137) |
| 35 | EXOME_CHIP | ss491438629 | May 04, 2012 (137) |
| 36 | CLINSEQ_SNP | ss491629964 | May 04, 2012 (137) |
| 37 | ILLUMINA | ss780682566 | Sep 08, 2015 (146) |
| 38 | ILLUMINA | ss783355920 | Sep 08, 2015 (146) |
| 39 | ILLUMINA | ss832841698 | Jul 13, 2019 (153) |
| 40 | EVA-GONL | ss987806023 | Aug 21, 2014 (142) |
| 41 | JMKIDD_LAB | ss1067514963 | Aug 21, 2014 (142) |
| 42 | 1000GENOMES | ss1338629996 | Aug 21, 2014 (142) |
| 43 | DDI | ss1426411435 | Apr 01, 2015 (144) |
| 44 | EVA_GENOME_DK | ss1575297185 | Apr 01, 2015 (144) |
| 45 | EVA_FINRISK | ss1584069487 | Apr 01, 2015 (144) |
| 46 | EVA_DECODE | ss1597479350 | Apr 01, 2015 (144) |
| 47 | EVA_UK10K_ALSPAC | ss1625198940 | Apr 01, 2015 (144) |
| 48 | EVA_UK10K_TWINSUK | ss1668192973 | Apr 01, 2015 (144) |
| 49 | EVA_EXAC | ss1690012445 | Apr 01, 2015 (144) |
| 50 | EVA_MGP | ss1711265817 | Apr 01, 2015 (144) |
| 51 | ILLUMINA | ss1751988354 | Sep 08, 2015 (146) |
| 52 | ILLUMINA | ss1917849828 | Feb 12, 2016 (147) |
| 53 | WEILL_CORNELL_DGM | ss1931172221 | Feb 12, 2016 (147) |
| 54 | ILLUMINA | ss1946289802 | Feb 12, 2016 (147) |
| 55 | ILLUMINA | ss1959285031 | Feb 12, 2016 (147) |
| 56 | JJLAB | ss2026314313 | Sep 14, 2016 (149) |
| 57 | ILLUMINA | ss2094788885 | Dec 20, 2016 (150) |
| 58 | ILLUMINA | ss2095016476 | Dec 20, 2016 (150) |
| 59 | USC_VALOUEV | ss2154591045 | Nov 08, 2017 (151) |
| 60 | HUMAN_LONGEVITY | ss2177158525 | Dec 20, 2016 (150) |
| 61 | ILLUMINA | ss2632748485 | Nov 08, 2017 (151) |
| 62 | ILLUMINA | ss2632748486 | Nov 08, 2017 (151) |
| 63 | GNOMAD | ss2738421518 | Nov 08, 2017 (151) |
| 64 | GNOMAD | ss2748441682 | Nov 08, 2017 (151) |
| 65 | GNOMAD | ss2892145620 | Nov 08, 2017 (151) |
| 66 | AFFY | ss2984920005 | Nov 08, 2017 (151) |
| 67 | AFFY | ss2985568278 | Nov 08, 2017 (151) |
| 68 | SWEGEN | ss3006968695 | Nov 08, 2017 (151) |
| 69 | ILLUMINA | ss3021264929 | Nov 08, 2017 (151) |
| 70 | ILLUMINA | ss3021264930 | Nov 08, 2017 (151) |
| 71 | CSHL | ss3349261894 | Nov 08, 2017 (151) |
| 72 | ILLUMINA | ss3626510066 | Oct 12, 2018 (152) |
| 73 | ILLUMINA | ss3634417891 | Oct 12, 2018 (152) |
| 74 | ILLUMINA | ss3636102348 | Oct 12, 2018 (152) |
| 75 | ILLUMINA | ss3637867317 | Oct 12, 2018 (152) |
| 76 | ILLUMINA | ss3640125232 | Oct 12, 2018 (152) |
| 77 | OMUKHERJEE_ADBS | ss3646413632 | Oct 12, 2018 (152) |
| 78 | ILLUMINA | ss3653690740 | Oct 12, 2018 (152) |
| 79 | EGCUT_WGS | ss3674380366 | Jul 13, 2019 (153) |
| 80 | EVA_DECODE | ss3690464597 | Jul 13, 2019 (153) |
| 81 | ACPOP | ss3737586809 | Jul 13, 2019 (153) |
| 82 | ILLUMINA | ss3744369919 | Jul 13, 2019 (153) |
| 83 | EVA | ss3748470124 | Jul 13, 2019 (153) |
| 84 | KHV_HUMAN_GENOMES | ss3813836613 | Jul 13, 2019 (153) |
| 85 | EVA | ss3824541051 | Apr 26, 2020 (154) |
| 86 | EVA | ss3825780782 | Apr 26, 2020 (154) |
| 87 | EVA | ss3832277284 | Apr 26, 2020 (154) |
| 88 | EVA | ss3839679847 | Apr 26, 2020 (154) |
| 89 | EVA | ss3845153521 | Apr 26, 2020 (154) |
| 90 | SGDP_PRJ | ss3874830818 | Apr 26, 2020 (154) |
| 91 | KRGDB | ss3922959416 | Apr 26, 2020 (154) |
| 92 | FSA-LAB | ss3983983395 | Apr 26, 2021 (155) |
| 93 | EVA | ss3985493316 | Apr 26, 2021 (155) |
| 94 | EVA | ss3986493486 | Apr 26, 2021 (155) |
| 95 | EVA | ss4017501573 | Apr 26, 2021 (155) |
| 96 | TOPMED | ss4862681874 | Apr 26, 2021 (155) |
| 97 | TOMMO_GENOMICS | ss6114217112 | Nov 01, 2024 (157) |
| 98 | EVA | ss6253832969 | Nov 01, 2024 (157) |
| 99 | EVA | ss6307413368 | Nov 01, 2024 (157) |
| 100 | EVA | ss6322395639 | Nov 01, 2024 (157) |
| 101 | YEGNASUBRAMANIAN_LAB | ss6343188212 | Nov 01, 2024 (157) |
| 102 | EVA | ss6349787586 | Nov 01, 2024 (157) |
| 103 | KOGIC | ss6382292616 | Nov 01, 2024 (157) |
| 104 | EVA | ss6404050393 | Nov 01, 2024 (157) |
| 105 | EVA | ss6404668861 | Nov 01, 2024 (157) |
| 106 | GNOMAD | ss6440426748 | Nov 01, 2024 (157) |
| 107 | GNOMAD | ss6859925579 | Nov 01, 2024 (157) |
| 108 | EVA | ss8236886087 | Nov 01, 2024 (157) |
| 109 | EVA | ss8237655810 | Nov 01, 2024 (157) |
| 110 | 1000G_HIGH_COVERAGE | ss8285093353 | Nov 01, 2024 (157) |
| 111 | EVA | ss8395331687 | Nov 01, 2024 (157) |
| 112 | HUGCELL_USP | ss8480551994 | Nov 01, 2024 (157) |
| 113 | EVA | ss8510130048 | Nov 01, 2024 (157) |
| 114 | EVA | ss8512473909 | Nov 01, 2024 (157) |
| 115 | 1000G_HIGH_COVERAGE | ss8579573366 | Nov 01, 2024 (157) |
| 116 | SANFORD_IMAGENETICS | ss8649889103 | Nov 01, 2024 (157) |
| 117 | TOMMO_GENOMICS | ss8745195958 | Nov 01, 2024 (157) |
| 118 | EVA | ss8799403703 | Nov 01, 2024 (157) |
| 119 | EVA | ss8800161212 | Nov 01, 2024 (157) |
| 120 | EVA | ss8824809270 | Nov 01, 2024 (157) |
| 121 | EVA | ss8848304503 | Nov 01, 2024 (157) |
| 122 | EVA | ss8880091626 | Nov 01, 2024 (157) |
| 123 | EVA | ss8941175434 | Nov 01, 2024 (157) |
| 124 | EVA | ss8980631493 | Nov 01, 2024 (157) |
| 125 | 1000Genomes | NC_000010.10 - 96702047 | Oct 12, 2018 (152) |
| 126 | 1000Genomes_30X | NC_000010.11 - 94942290 | Nov 01, 2024 (157) |
| 127 | The Avon Longitudinal Study of Parents and Children | NC_000010.10 - 96702047 | Oct 12, 2018 (152) |
| 128 | Genetic variation in the Estonian population | NC_000010.10 - 96702047 | Oct 12, 2018 (152) |
| 129 | ExAC | NC_000010.10 - 96702047 | Oct 12, 2018 (152) |
| 130 | FINRISK | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 131 | The Danish reference pan genome | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 132 | gnomAD v4 - Exomes | NC_000010.11 - 94942290 | Nov 01, 2024 (157) |
| 133 | gnomAD v4 - Genomes | NC_000010.11 - 94942290 | Nov 01, 2024 (157) |
| 134 | Genome of the Netherlands Release 5 | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 135 | HapMap | NC_000010.11 - 94942290 | Apr 26, 2020 (154) |
| 136 | KOREAN population from KRGDB | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 137 | Korean Genome Project 4K | NC_000010.11 - 94942290 | Nov 01, 2024 (157) |
| 138 | Medical Genome Project healthy controls from Spanish population | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 139 | Northern Sweden | NC_000010.10 - 96702047 | Jul 13, 2019 (153) |
| 140 | Ancient Sardinia genome-wide 1240k capture data generation and analysis | NC_000010.10 - 96702047 | Apr 26, 2021 (155) |
| 141 | PharmGKB Aggregated | NC_000010.11 - 94942290 | Apr 26, 2020 (154) |
| 142 | Qatari | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 143 | SGDP_PRJ | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 144 | Siberian | NC_000010.10 - 96702047 | Apr 26, 2020 (154) |
| 145 | 38KJPN | NC_000010.11 - 94942290 | Nov 01, 2024 (157) |
| 146 | TopMed | NC_000010.11 - 94942290 | Apr 26, 2021 (155) |
| 147 | UK 10K study - Twins | NC_000010.10 - 96702047 | Oct 12, 2018 (152) |
| 148 | ALFA | NC_000010.11 - 94942290 | Nov 01, 2024 (157) |
| 149 | ClinVar | RCV000008920.10 | Nov 01, 2024 (157) |
| 150 | ClinVar | RCV000150377.13 | Nov 01, 2024 (157) |
| 151 | ClinVar | RCV000150378.13 | Nov 01, 2024 (157) |
| 152 | ClinVar | RCV000154312.13 | Nov 01, 2024 (157) |
| 153 | ClinVar | RCV000309101.12 | Nov 01, 2024 (157) |
| 154 | ClinVar | RCV000723560.12 | Nov 01, 2024 (157) |
| 155 | ClinVar | RCV000787929.10 | Nov 01, 2024 (157) |
| 156 | ClinVar | RCV000788093.10 | Nov 01, 2024 (157) |
| 157 | ClinVar | RCV000788099.10 | Nov 01, 2024 (157) |
| 158 | ClinVar | RCV001263463.10 | Nov 01, 2024 (157) |
Help
History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).
| Associated ID | History Updated (Build) |
|---|---|
| rs17110268 | Dec 02, 2004 (124) |
| rs28371674 | Aug 07, 2014 (136) |
| rs33968134 | May 23, 2006 (127) |
| rs60690363 | May 26, 2008 (130) |
Added to this RefSNP Cluster:
| Submission IDs | Observation SPDI | Canonical SPDI | Source RSIDs |
|---|---|---|---|
| ss8512473909 | NC_000010.10:96702046:C:A | NC_000010.11:94942289:C:A | (self) |
| ss88317380, ss174703200, ss207463445, ss254535320, ss491629964, ss1597479350 | NC_000010.9:96692036:C:T | NC_000010.11:94942289:C:T | (self) |
| 51061591, 28348703, 20118614, 242102, 65948, 2283138, 12640837, 30136810, 381577, 10871674, 719243, 13214151, 26847798, 7107399, 28348703, ss336318562, ss342304157, ss481066559, ss491001666, ss491438629, ss780682566, ss783355920, ss832841698, ss987806023, ss1067514963, ss1338629996, ss1426411435, ss1575297185, ss1584069487, ss1625198940, ss1668192973, ss1690012445, ss1711265817, ss1751988354, ss1917849828, ss1931172221, ss1946289802, ss1959285031, ss2026314313, ss2094788885, ss2095016476, ss2154591045, ss2632748485, ss2632748486, ss2738421518, ss2748441682, ss2892145620, ss2984920005, ss2985568278, ss3006968695, ss3021264929, ss3021264930, ss3349261894, ss3626510066, ss3634417891, ss3636102348, ss3637867317, ss3640125232, ss3646413632, ss3653690740, ss3674380366, ss3737586809, ss3744369919, ss3748470124, ss3824541051, ss3825780782, ss3832277284, ss3839679847, ss3874830818, ss3922959416, ss3983983395, ss3985493316, ss3986493486, ss4017501573, ss6253832969, ss6307413368, ss6322395639, ss6343188212, ss6349787586, ss6404668861, ss8395331687, ss8510130048, ss8512473909, ss8649889103, ss8799403703, ss8800161212, ss8824809270, ss8848304503, ss8941175434, ss8980631493 | NC_000010.10:96702046:C:T | NC_000010.11:94942289:C:T | (self) |
| RCV000008920.10, RCV000154312.13, RCV000309101.12, RCV000723560.12, RCV000787929.10, RCV000788093.10, RCV000788099.10, RCV001263463.10, 67099301, 35748587, 387061364, 468353, 32144514, 1148, 131592932, 78227529, 10410914457, ss244238828, ss256302166, ss2177158525, ss3690464597, ss3813836613, ss3845153521, ss4862681874, ss6114217112, ss6382292616, ss6404050393, ss6440426748, ss6859925579, ss8236886087, ss8237655810, ss8285093353, ss8480551994, ss8579573366, ss8745195958, ss8880091626 | NC_000010.11:94942289:C:T | NC_000010.11:94942289:C:T | (self) |
| ss52052050 | NT_030059.12:15450572:C:T | NC_000010.11:94942289:C:T | (self) |
| ss2419885, ss4049526, ss5288363, ss5586420, ss12588496, ss32475972, ss38570128, ss48404892, ss69365623, ss69366431, ss69367174, ss69367460, ss84158178, ss105107894, ss105108089, ss105109746, ss105109762, ss153736100, ss159329689, ss159721125, ss160462691, ss172924182, ss410916035 | NT_030059.13:47506510:C:T | NC_000010.11:94942289:C:T | (self) |
Help
Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.
274
citations for rs1799853
| PMID | Title | Author | Year | Journal |
|---|---|---|---|---|
| 8004131 | Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. | Rettie AE et al. | 1994 | Pharmacogenetics |
| 10073515 | Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. | Aithal GP et al. | 1999 | Lancet (London, England) |
| 10961881 | Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. | Taube J et al. | 2000 | Blood |
| 11926893 | Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. | Higashi MK et al. | 2002 | JAMA |
| 11966680 | CYP2C9 polymorphism and warfarin dose requirements. | Daly AK et al. | 2002 | British journal of clinical pharmacology |
| 12496751 | Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. | Scordo MG et al. | 2002 | Clinical pharmacology and therapeutics |
| 15001971 | CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. | Peyvandi F et al. | 2004 | Clinical pharmacology and therapeutics |
| 15590403 | Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. | D'Ambrosio RL et al. | 2004 | Haematologica |
| 15608560 | Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. | King BP et al. | 2004 | Pharmacogenetics |
| 15714076 | CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. | Sanderson S et al. | 2005 | Genetics in medicine |
| 15841315 | Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. | Voora D et al. | 2005 | Thrombosis and haemostasis |
| 15883587 | Common VKORC1 and GGCX polymorphisms associated with warfarin dose. | Wadelius M et al. | 2005 | The pharmacogenomics journal |
| 15947090 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. | Sconce EA et al. | 2005 | Blood |
| 16160068 | A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. | Hillman MA et al. | 2005 | Clinical medicine & research |
| 16493479 | Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. | Vecsler M et al. | 2006 | Thrombosis and haemostasis |
| 16595073 | Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations. | Savas S et al. | 2006 | Human genomics |
| 16611750 | Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. | Li T et al. | 2006 | Journal of medical genetics |
| 17048007 | Association of warfarin dose with genes involved in its action and metabolism. | Wadelius M et al. | 2007 | Human genetics |
| 17111199 | Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. | Carlquist JF et al. | 2006 | Journal of thrombosis and thrombolysis |
| 17387222 | Genetic-based dosing in orthopedic patients beginning warfarin therapy. | Millican EA et al. | 2007 | Blood |
| 17510308 | Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. | Zhu Y et al. | 2007 | Clinical chemistry |
| 17653141 | Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. | Limdi NA et al. | 2008 | Clinical pharmacology and therapeutics |
| 17851566 | CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. | Caraco Y et al. | 2008 | Clinical pharmacology and therapeutics |
| 17989110 | Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. | Anderson JL et al. | 2007 | Circulation |
| 18305455 | Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. | Gage BF et al. | 2008 | Clinical pharmacology and therapeutics |
| 18322281 | Genetic determinants of response to warfarin during initial anticoagulation. | Schwarz UI et al. | 2008 | The New England journal of medicine |
| 18466099 | Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. | Limdi NA et al. | 2008 | Pharmacogenomics |
| 18542936 | VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. | Oner Ozgon G et al. | 2008 | European journal of clinical pharmacology |
| 18547414 | Genotyping panel for assessing response to cancer chemotherapy. | Dai Z et al. | 2008 | BMC medical genomics |
| 18574025 | The largest prospective warfarin-treated cohort supports genetic forecasting. | Wadelius M et al. | 2009 | Blood |
| 18596683 | Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. | Schelleman H et al. | 2008 | Clinical pharmacology and therapeutics |
| 18662264 | Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. | Lenzini PA et al. | 2008 | Journal of thrombosis and haemostasis |
| 18680736 | Genetic factors contribute to patient-specific warfarin dose for Han Chinese. | Wang TL et al. | 2008 | Clinica chimica acta; international journal of clinical chemistry |
| 18752379 | Warfarin pharmacogenetics. | Limdi NA et al. | 2008 | Pharmacotherapy |
| 18836275 | The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement. | Yildirim H et al. | 2008 | Medical principles and practice |
| 18990750 | Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. | Cotterchio M et al. | 2008 | Cancer epidemiology, biomarkers & prevention |
| 18992148 | Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. | Küry S et al. | 2008 | BMC cancer |
| 18992263 | Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. | Slattery ML et al. | 2009 | Mutation research |
| 19031075 | Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. | Lindh JD et al. | 2009 | European journal of clinical pharmacology |
| 19223558 | Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. | Chang ET et al. | 2009 | Cancer epidemiology, biomarkers & prevention |
| 19228618 | Estimation of the warfarin dose with clinical and pharmacogenetic data. | Klein TE et al. | 2009 | The New England journal of medicine |
| 19297219 | Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. | Limdi NA et al. | 2009 | Blood cells, molecules & diseases |
| 19300499 | A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. | Takeuchi F et al. | 2009 | PLoS genetics |
| 19376514 | Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. | Su HI et al. | 2010 | Fertility and sterility |
| 19387626 | Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. | Fuchshuber-Moraes M et al. | 2009 | European journal of clinical pharmacology |
| 19422321 | Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? | Agúndez JA et al. | 2009 | Expert opinion on drug metabolism & toxicology |
| 19538716 | Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores). | Branco CC et al. | 2009 | Thrombosis journal |
| 19617466 | CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. | Hennessy S et al. | 2009 | Journal of clinical pharmacology |
| 19679631 | Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. | Linder MW et al. | 2009 | Clinical chemistry |
| 19736056 | Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. | Gold LS et al. | 2009 | Cancer epidemiology |
| 19745563 | VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. | Sandanaraj E et al. | 2009 | Drug metabolism and pharmacokinetics |
| 19761371 | Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. | Daily EB et al. | 2009 | Pharmacogenomics |
| 19794411 | Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. | Pautas E et al. | 2010 | Clinical pharmacology and therapeutics |
| 19802360 | Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. | Limdi N et al. | 2007 | Personalized medicine |
| 19822571 | Genetic variations in xenobiotic metabolic pathway genes, personal hair dye use, and risk of non-Hodgkin lymphoma. | Zhang Y et al. | 2009 | American journal of epidemiology |
| 19874474 | Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. | Ferder NS et al. | 2010 | Journal of thrombosis and haemostasis |
| 19955245 | Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. | Moyer TP et al. | 2009 | Mayo Clinic proceedings |
| 20029944 | Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. | Han X et al. | 2010 | American journal of hematology |
| 20072124 | Genetic and clinical predictors of warfarin dose requirements in African Americans. | Cavallari LH et al. | 2010 | Clinical pharmacology and therapeutics |
| 20082485 | Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. | Báez S et al. | 2010 | World journal of gastroenterology |
| 20131310 | Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of non-Hodgkin lymphoma. | Li Y et al. | 2010 | American journal of hematology |
| 20149073 | Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. | Pérez-Andreu V et al. | 2010 | Journal of thrombosis and haemostasis |
| 20150829 | Cytochrome P450 2C9-CYP2C9. | Van Booven D et al. | 2010 | Pharmacogenetics and genomics |
| 20203262 | Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. | Limdi NA et al. | 2010 | Blood |
| 20214591 | Pharmacogenomics in aspirin intolerance. | Agúndez JA et al. | 2009 | Current drug metabolism |
| 20375999 | Integration of genetic, clinical, and INR data to refine warfarin dosing. | Lenzini P et al. | 2010 | Clinical pharmacology and therapeutics |
| 20421126 | A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. | Wells PS et al. | 2010 | Thrombosis research |
| 20436251 | Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma. | Ferrucci LM et al. | 2010 | World review of nutrition and dietetics |
| 20459744 | Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. | Gor PP et al. | 2010 | Breast cancer research |
| 20521218 | Progress toward genetic tailoring of heart failure therapy. | Lillvis JH et al. | 2010 | Current opinion in molecular therapeutics |
| 20555338 | Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. | Ross KA et al. | 2010 | Journal of human genetics |
| 20585445 | A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. | Verde Z et al. | 2010 | PloS one |
| 20709439 | Warfarin dosing in patients with impaired kidney function. | Limdi NA et al. | 2010 | American journal of kidney diseases |
| 20716240 | New genetic variant that might improve warfarin dose prediction in African Americans. | Schelleman H et al. | 2010 | British journal of clinical pharmacology |
| 20733952 | Warfarin genotyping using three different platforms. | Lefferts JA et al. | 2010 | American journal of translational research |
| 20808793 | Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? | Durrmeyer X et al. | 2010 | PloS one |
| 20833980 | In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. | Nowak-Göttl U et al. | 2010 | Blood |
| 20847277 | Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. | Baak-Pablo R et al. | 2010 | The Journal of molecular diagnostics |
| 20854800 | Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays. | Li Y et al. | 2011 | Clinica chimica acta; international journal of clinical chemistry |
| 20921971 | Mapping genes that predict treatment outcome in admixed populations. | Baye TM et al. | 2010 | The pharmacogenomics journal |
| 20936101 | Pharmacogenetics of Anti-Diabetes Drugs. | Distefano JK et al. | 2010 | Pharmaceuticals (Basel, Switzerland) |
| 20937634 | Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. | Cleary SP et al. | 2010 | American journal of epidemiology |
| 21110013 | Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. | Geisen C et al. | 2011 | European journal of clinical pharmacology |
| 21110192 | Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. | Gan GG et al. | 2011 | Annals of hematology |
| 21127708 | Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. | Kringen MK et al. | 2011 | Journal of biomedicine & biotechnology |
| 21132113 | Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare. | Loud JT et al. | 2010 | The journal for nurse practitioners |
| 21148049 | Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. | Esmerian MO et al. | 2011 | Journal of clinical pharmacology |
| 21174619 | VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. | Zambon CF et al. | 2011 | Pharmacogenomics |
| 21185752 | Pharmacogenomics of warfarin dose requirements in Hispanics. | Cavallari LH et al. | 2011 | Blood cells, molecules & diseases |
| 21219403 | Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. | Zhang Q et al. | 2011 | British journal of clinical pharmacology |
| 21228733 | Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. | Shahin MH et al. | 2011 | Pharmacogenetics and genomics |
| 21270790 | The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. | Perera MA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21320153 | Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. | Botton MR et al. | 2011 | British journal of clinical pharmacology |
| 21428770 | Genomics and drug response. | Wang L et al. | 2011 | The New England journal of medicine |
| 21441355 | Detection of common single nucleotide polymorphisms synthesizing quantitative trait association of rarer causal variants. | Takeuchi F et al. | 2011 | Genome research |
| 21450715 | High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. | Cosgun E et al. | 2011 | Bioinformatics (Oxford, England) |
| 21474949 | Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma. | Ferrucci LM et al. | 2010 | Journal of nutrigenetics and nutrigenomics |
| 21480951 | Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. | Lim JS et al. | 2011 | British journal of clinical pharmacology |
| 21532843 | Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. | Pinheiro SP et al. | 2010 | International journal of molecular epidemiology and genetics |
| 21562147 | Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. | Zhang X et al. | 2011 | Drug metabolism and disposition |
| 21575037 | Population diversity and the performance of warfarin dosing algorithms. | Suarez-Kurtz G et al. | 2011 | British journal of clinical pharmacology |
| 21639946 | Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. | Suriapranata IM et al. | 2011 | BMC medical genetics |
| 21691466 | Genetics of warfarin sensitivity in an emergency department population with thromboembolic. | Johnson SW et al. | 2011 | The western journal of emergency medicine |
| 21692828 | The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. | Lane S et al. | 2012 | British journal of clinical pharmacology |
| 21708280 | Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. | Srivastava K et al. | 2011 | Mutation research |
| 21883387 | Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. | Lacut K et al. | 2012 | British journal of clinical pharmacology |
| 21900891 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. | Johnson JA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21918509 | Pharmacogenomics: application to the management of cardiovascular disease. | Johnson JA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21966275 | Large-scale gene-centric analysis identifies novel variants for coronary artery disease. | 2011 | PLoS genetics | |
| 22010099 | VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. | Biss TT et al. | 2012 | Blood |
| 22114699 | Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. | Gong IY et al. | 2011 | PloS one |
| 22116191 | The Creating an Optimal Warfarin Nomogram (CROWN) Study. | Perlstein TS et al. | 2012 | Thrombosis and haemostasis |
| 22118051 | Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. | Dandara C et al. | 2011 | Pharmacogenomics |
| 22126607 | Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. | Huang C et al. | 2011 | Genome medicine |
| 22130800 | Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. | Moreau C et al. | 2012 | Blood |
| 22186998 | Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. | Horne BD et al. | 2012 | Thrombosis and haemostasis |
| 22329724 | Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. | Ramirez AH et al. | 2012 | Pharmacogenomics |
| 22349464 | A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. | Cini M et al. | 2012 | European journal of clinical pharmacology |
| 22486182 | Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. | Smires FZ et al. | 2012 | Journal of clinical pharmacy and therapeutics |
| 22491019 | Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. | Martis S et al. | 2013 | The pharmacogenomics journal |
| 22552919 | Bioinformatics and variability in drug response: a protein structural perspective. | Lahti JL et al. | 2012 | Journal of the Royal Society, Interface |
| 22569204 | PharmGKB summary: phenytoin pathway. | Thorn CF et al. | 2012 | Pharmacogenetics and genomics |
| 22594507 | A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. | Andersson ML et al. | 2012 | Pharmacogenomics |
| 22645715 | Xenobiotic metabolizing gene variants and renal cell cancer: a multicenter study. | Heck JE et al. | 2012 | Frontiers in oncology |
| 22676192 | Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. | Pavani A et al. | 2012 | Pharmacogenomics |
| 22676711 | Pharmacogenomics of warfarin in populations of African descent. | Suarez-Kurtz G et al. | 2013 | British journal of clinical pharmacology |
| 22702493 | Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. | Seredina TA et al. | 2012 | BMC medical genetics |
| 22754184 | Pharmacogenetic aspects of coumarinic oral anticoagulant therapies. | Rathore SS et al. | 2011 | Indian journal of clinical biochemistry |
| 22911785 | An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. | Borobia AM et al. | 2012 | PloS one |
| 22938532 | Sequencing and analysis of a South Asian-Indian personal genome. | Gupta R et al. | 2012 | BMC genomics |
| 22990331 | CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. | Santos PC et al. | 2013 | European journal of clinical pharmacology |
| 22992668 | Pharmacogenomics knowledge for personalized medicine. | Whirl-Carrillo M et al. | 2012 | Clinical pharmacology and therapeutics |
| 23016735 | Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? | Belozerceva LA et al. | 2012 | The EPMA journal |
| 23081681 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. | Barry EL et al. | 2013 | Cancer causes & control |
| 23130019 | Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations. | Roco A et al. | 2012 | Frontiers in genetics |
| 23133420 | Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin. | Suarez-Kurtz G et al. | 2012 | Frontiers in pharmacology |
| 23226040 | Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. | O'Rielly DD et al. | 2010 | Pharmacogenomics and personalized medicine |
| 23226061 | The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. | Williams PJ et al. | 2012 | Pharmacogenomics and personalized medicine |
| 23237631 | Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. | Carcas AJ et al. | 2012 | Trials |
| 23279643 | The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. | Biss TT et al. | 2013 | Journal of thrombosis and haemostasis |
| 23285254 | Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans. | Patillon B et al. | 2012 | PloS one |
| 23299405 | Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps. | Fu Z et al. | 2013 | Carcinogenesis |
| 23300409 | Chapter 7: Pharmacogenomics. | Karczewski KJ et al. | 2012 | PLoS computational biology |
| 23473641 | Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. | Krishna Kumar D et al. | 2013 | Thrombosis research |
| 23587916 | Allele frequency distribution of CYP2C9 2 and CYP2C9 3 polymorphisms in six Mexican populations. | Castelán-Martínez OD et al. | 2013 | Gene |
| 23691226 | Novel associations of VKORC1 variants with higher acenocoumarol requirements. | Anton AI et al. | 2013 | PloS one |
| 23766564 | Pharmacogenetics of chronic pain and its treatment. | Světlík S et al. | 2013 | Mediators of inflammation |
| 23797323 | Pharmacogenomics of anti-platelet and anti-coagulation therapy. | Fisch AS et al. | 2013 | Current cardiology reports |
| 23876492 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. | DeGorter MK et al. | 2013 | Circulation. Cardiovascular genetics |
| 23946381 | Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. | Ma X et al. | 2014 | Gut |
| 23990957 | Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. | Mazzaccara C et al. | 2013 | PloS one |
| 24018621 | Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. | Hernandez W et al. | 2014 | The pharmacogenomics journal |
| 24019055 | Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. | Krishna Kumar D et al. | 2014 | European journal of clinical pharmacology |
| 24282029 | Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. | Gordon AS et al. | 2014 | Human molecular genetics |
| 24368493 | Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese. | Chi LF et al. | 2014 | Neuroreport |
| 24442125 | CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. | Klen J et al. | 2014 | European journal of clinical pharmacology |
| 24627758 | Low budget analysis of Direct-To-Consumer genomic testing familial data. | Glusman G et al. | 2012 | F1000Research |
| 24779372 | Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogenetics. | Yang HC et al. | 2014 | BMC genomics |
| 24787444 | An ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care. | Miñarro-Giménez JA et al. | 2014 | PloS one |
| 24944790 | Screening for 392 polymorphisms in 141 pharmacogenes. | Kim JY et al. | 2014 | Biomedical reports |
| 25207010 | Polymorphisms of cytochrome p450 genes in three ethnic groups from Russia. | Korytina G et al. | 2012 | Balkan medical journal |
| 25266489 | Genetic polymorphisms of VIP variants in the Tajik ethnic group of northwest China. | Zhang J et al. | 2014 | BMC genetics |
| 25388680 | Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage. | Donnelly MK et al. | 2015 | Journal of cerebral blood flow and metabolism |
| 25419701 | Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. | Bonifaz-Peña V et al. | 2014 | PloS one |
| 25534367 | Genetic polymorphisms of ALOX5AP and CYP3A5 increase susceptibility to ischemic stroke and are associated with atherothrombotic events in stroke patients. | Yi X et al. | 2015 | Journal of stroke and cerebrovascular diseases |
| 25714468 | A systematic approach to the reporting of medically relevant findings from whole genome sequencing. | McLaughlin HM et al. | 2014 | BMC medical genetics |
| 25719551 | The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms. | Gross-Davis CA et al. | 2015 | International journal of environmental research and public health |
| 25839935 | CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke. | Yi X et al. | 2015 | Gene |
| 26010205 | Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. | Abohelaika S et al. | 2015 | Journal of thrombosis and haemostasis |
| 26091847 | Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China. | Wang L et al. | 2015 | BMC genetics |
| 26238769 | Impact of regular physical activity on weekly warfarin dose requirement. | Rouleau-Mailloux É et al. | 2016 | Journal of thrombosis and thrombolysis |
| 26265036 | Genome-wide association study of warfarin maintenance dose in a Brazilian sample. | Parra EJ et al. | 2015 | Pharmacogenomics |
| 26516523 | Pharmacogenetics of analgesic drugs. | Cregg R et al. | 2013 | British journal of pain |
| 26739746 | A multi-factorial analysis of response to warfarin in a UK prospective cohort. | Bourgeois S et al. | 2016 | Genome medicine |
| 26785747 | Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. | Iskakova AN et al. | 2016 | BMC genetics |
| 26858644 | Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling. | Chua EW et al. | 2016 | Frontiers in pharmacology |
| 26961113 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. | Yi X et al. | 2016 | Journal of atherosclerosis and thrombosis |
| 26977927 | A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. | Tong HY et al. | 2016 | PloS one |
| 27087514 | Interactions Among CYP2C8, EPHX2, and CYP4A11 Variants and CYP Plasma Metabolite Levels in Ischemic Stroke. | Yi X et al. | 2016 | Journal of atherosclerosis and thrombosis |
| 27233804 | Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China. | Jin T et al. | 2016 | BMC genetics |
| 27296832 | ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. | Fukunaga K et al. | 2016 | BMC genetics |
| 27347941 | Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes. | Costa V et al. | 2016 | International journal of molecular sciences |
| 27453700 | Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. | Marek E et al. | 2016 | The journal of pediatric pharmacology and therapeutics |
| 27529241 | The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? | Daud AN et al. | 2016 | International journal of molecular sciences |
| 27555891 | Pharmacogenetic studies update in type 2 diabetes mellitus. | Singh S et al. | 2016 | World journal of diabetes |
| 27636550 | A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. | Mizzi C et al. | 2016 | PloS one |
| 27767381 | The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment. | Sortica VA et al. | 2016 | Pharmacogenomics |
| 28029011 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. | Kim S et al. | 2017 | Annals of laboratory medicine |
| 28049362 | Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. | Gaikwad T et al. | 2018 | Clinical and applied thrombosis/hemostasis |
| 28158543 | Supporting precision medicine by data mining across multi-disciplines: an integrative approach for generating comprehensive linkages between single nucleotide variants (SNVs) and drug-binding sites. | Roy Choudhury A et al. | 2017 | Bioinformatics (Oxford, England) |
| 28384046 | Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform. | Langaee T et al. | 2017 | Genetic testing and molecular biomarkers |
| 28603633 | In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane. | Peterson A et al. | 2017 | Pharmacology research & perspectives |
| 28609430 | Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus. | Smith CJ et al. | 2017 | Pediatric research |
| 28620303 | Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. | Zhang JE et al. | 2017 | Frontiers in pharmacology |
| 28750087 | Risk prediction of developing venous thrombosis in combined oral contraceptive users. | McDaid A et al. | 2017 | PloS one |
| 28867752 | Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin. | Arunkumar G et al. | 2017 | Drug discoveries & therapeutics |
| 29133890 | Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia. | Zakerska-Banaszak O et al. | 2017 | Scientific reports |
| 29193749 | Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. | Borobia AM et al. | 2018 | Clinical and translational science |
| 29218998 | VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. | Mili FD et al. | 2018 | Future cardiology |
| 29425227 | Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. | Sheth H et al. | 2018 | PloS one |
| 29681089 | Genetic variation in biotransformation enzymes, air pollution exposures, and risk of spina bifida. | Padula AM et al. | 2018 | American journal of medical genetics. Part A |
| 29776219 | A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. | Gladding P et al. | 2010 | Personalized medicine |
| 30068618 | Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. | Collin LJ et al. | 2018 | BMJ open |
| 30135636 | The role of pharmacogenetics of cytochrome P450s in phenytoin-induced DRESS syndrome. | Yaşar Ü et al. | 2018 | Central-European journal of immunology |
| 30214584 | Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. | Feng W et al. | 2018 | Oncology letters |
| 30360443 | Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population. | Ahmed S et al. | 2018 | Genes |
| 30409984 | Assessment of coding region variants in Kuwaiti population: implications for medical genetics and population genomics. | John SE et al. | 2018 | Scientific reports |
| 30452466 | Characterization of ADME genes variation in Roma and 20 populations worldwide. | Škarić-Jurić T et al. | 2018 | PloS one |
| 30486437 | Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy. | Al-Eitan LN et al. | 2018 | Genes |
| 30515958 | Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. | Mannino GC et al. | 2019 | Diabetes/metabolism research and reviews |
| 30518301 | CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. | Claudio-Campos KI et al. | 2019 | Pharmacogenomics |
| 30712247 | Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. | Kocael A et al. | 2019 | Molecular biology reports |
| 30758238 | Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. | Langaee T et al. | 2019 | Genetic testing and molecular biomarkers |
| 30866412 | VKORC1 and CYP2C9 Polymorphisms: A Case Report in a Dutch Family with Pulmonary Fibrosis. | Wijnen P et al. | 2019 | International journal of molecular sciences |
| 30933373 | Warfarin dose requirement in patients having severe thrombosis or thrombophilia. | Helin TA et al. | 2019 | British journal of clinical pharmacology |
| 31019283 | Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. | Thauvin-Robinet C et al. | 2019 | European journal of human genetics |
| 31061616 | Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. | Al-Eitan LN et al. | 2019 | Saudi pharmaceutical journal |
| 31086207 | Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. | Afsar NA et al. | 2019 | Scientific reports |
| 31270413 | ||||
| 31395958 | Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. | de Oliveira Magalhães Mourão A et al. | 2020 | The pharmacogenomics journal |
| 31411557 | Pharmacogenomic considerations for medications in the perioperative setting. | Jhun EH et al. | 2019 | Pharmacogenomics |
| 31447576 | Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. | da Silveira MMBM et al. | 2019 | The application of clinical genetics |
| 31584773 | Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo population. | Alvarado ÁT et al. | 2019 | Biomedica |
| 31709648 | The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide. | Chen L et al. | 2020 | Diabetic medicine |
| 31720756 | Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. | Praxedes MFS et al. | 2020 | European journal of clinical pharmacology |
| 31818908 | Systematic meta-analyses, field synopsis and global assessment of the evidence of genetic association studies in colorectal cancer. | Montazeri Z et al. | 2020 | Gut |
| 31854268 | Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients. | Li W et al. | 2020 | Pharmacogenomics |
| 31869433 | Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. | Asiimwe IG et al. | 2020 | Clinical pharmacology and therapeutics |
| 32228310 | Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. | Rojo M et al. | 2020 | Clinical and applied thrombosis/hemostasis |
| 32276000 | Genetic variations in drug-metabolizing enzyme CYP2C9 among major ethnic groups of Pakistani population. | Hizbullah et al. | 2020 | Gene |
| 32303955 | Clinically relevant pharmacogenetic markers in Tatars and Balkars. | Abdullaev SP et al. | 2020 | Molecular biology reports |
| 32326111 | Role of Genetic Variations in the Hepatic Handling of Drugs. | Marin JJG et al. | 2020 | International journal of molecular sciences |
| 32327994 | A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. | Roco A et al. | 2020 | Frontiers in pharmacology |
| 32380173 | Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists. | Pratt VM et al. | 2020 | The Journal of molecular diagnostics |
| 32457604 | Possible Genetic Determinants of Response to Phenytoin in a Group of Colombian Patients With Epilepsy. | Calderon-Ospina CA et al. | 2020 | Frontiers in pharmacology |
| 32567426 | An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children. | Makowska M et al. | 2021 | The International journal of neuroscience |
| 32575674 | rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. | Naja K et al. | 2020 | Journal of personalized medicine |
| 32586526 | Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. | Van Driest SL et al. | 2020 | The Journal of pediatrics |
| 32639515 | Bayesian Pathway Analysis for Complex Interactions. | Baurley JW et al. | 2020 | American journal of epidemiology |
| 33192522 | Pleiotropic Functions of Cytochrome P450 Monooxygenase-Derived Eicosanoids in Cancer. | Luo Y et al. | 2020 | Frontiers in pharmacology |
| 33262486 | Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: e-Posters. | 2020 | European journal of human genetics | |
| 33346480 | [The pharmacogenetics of hypoglycemia and the glycemic variability at the patients ith type 2 diabetes mellitus]. | Chernikova NA et al. | 2020 | Terapevticheskii arkhiv |
| 33519226 | Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. | Fernandes MR et al. | 2021 | Pharmacogenomics and personalized medicine |
| 33580125 | Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. | Duflot T et al. | 2021 | Scientific reports |
| 33637672 | Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. | Wang B et al. | 2021 | Signal transduction and targeted therapy |
| 33688237 | Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype. | Fonseca DJ et al. | 2021 | Pharmacogenomics and personalized medicine |
| 33804537 | Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters. | Iannaccone T et al. | 2021 | Pharmaceuticals (Basel, Switzerland) |
| 33805706 | SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. | Zubiaur P et al. | 2021 | Journal of personalized medicine |
| 33811620 | Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. | Sridharan K et al. | 2021 | Pharmacological reports |
| 33840516 | Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis. | Yee J et al. | 2021 | Clinical therapeutics |
| 33995083 | Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. | Mejía-Abril G et al. | 2021 | Frontiers in pharmacology |
| 34149005 | Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan. | Huang YS et al. | 2021 | Pharmacogenetics and genomics |
| 34382722 | Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. | Ndadza A et al. | 2021 | Journal of thrombosis and haemostasis |
| 34385834 | Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process. | Borro M et al. | 2021 | Pharmacogenomics and personalized medicine |
| 34498315 | The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. | Wu L et al. | 2021 | Journal of clinical laboratory analysis |
| 34559488 | Retrospective pharmacogenetic analysis of a pediatric patient under anticoagulant treatment: Clinical case. | Cavieres M et al. | 2021 | Biomedica |
| 34621165 | Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. | Macías Y et al. | 2021 | Frontiers in pharmacology |
| 34621706 | Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform. | Kim B et al. | 2021 | Translational and clinical pharmacology |
| 34690761 | Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. | Villapalos-García G et al. | 2021 | Frontiers in pharmacology |
| 34802403 | Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients. | Kumar DK et al. | 2021 | Current drug metabolism |
| 34900058 | Genetic polymorphism of CYP3A4 is associated with poor response to ifosfamide treatment in children with solid embryonic tumors. | Espindola LMT et al. | 2021 | Archives of medical science |
| 34920277 | Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms. | Stajnko A et al. | 2022 | Environment international |
| 34958284 | Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. | Muyambo S et al. | 2022 | Omics |
| 35089958 | Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. | Goljan E et al. | 2022 | PloS one |
| 35136381 | Genetic Analysis of CYP2C9 with Reference to Drug Response in Epilepsy Patients of Pakistan. | Maqbool H et al. | 2022 | Genetics research |
| 35337356 | Cross-ethnic analysis of common gene variants in hemostasis show lopsided representation of global populations in genetic databases. | Osman A et al. | 2022 | BMC medical genomics |
| 35757332 | Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement. | Shafique H et al. | 2022 | Frontiers in cardiovascular medicine |
| 35761855 | Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. | Nthontho KC et al. | 2022 | Pharmacogenomics and personalized medicine |
| 36065758 | CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride. | Campodónico DM et al. | 2022 | Clinical and translational science |
| 36076616 | Pharmacogenetics of siponimod: A systematic review. | Díaz-Villamarín X et al. | 2022 | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |
| 36164570 | Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard. | Alshabeeb MA et al. | 2022 | Saudi pharmaceutical journal |
| 36210801 | A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients. | Asiimwe IG et al. | 2022 | Frontiers in pharmacology |
| 36211438 | Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation. | Muñiz P et al. | 2022 | Frontiers in immunology |
| 37457231 | Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives. | Coons JC et al. | 2023 | Pharmacogenomics and personalized medicine |
Help
The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.
Genome context:
Select flank length:
Genomic regions, transcripts, and products
Top▲
Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.